Methods and compositions for treating mucosal tissue disorders
The present invention provides compositions and formulations comprising glutathione with or without thiocyanate and methods of use thereof to treat diseases and disorders in mucosal/epithelial tissue.
1. A method for treating a pulmonary or airway disorder or disease by inhibiting microbial growth in an airway of a subject in need thereof, comprising administering to the airway of the subject an effective amount of a composition comprising:
a) a glutathione, or a pharmaceutically-acceptable salt of glutathione;
b) an organic acid or a pharmaceutically-acceptable salt of an organic acid; and
c) a bicarbonate salt,
wherein the pulmonary or airway disorder or disease is selected from the group consisting of chronic inflammatory lung disease, inflammation and/or infection associated with lung transplantation, acute lung rejection, asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD) and any combination thereof, thereby treating the pulmonary or airway disorder or disease by inhibiting microbial growth in the airway of the subject.
2. The method of claim 1 , wherein the organic acid is ascorbic acid.
3. The method of claim 1 , wherein the bicarbonate salt is sodium bicarbonate or potassium bicarbonate.
4. The method of claim 1 , wherein the amount of each of component (a), (b) and (c) of the composition is present such that the amount of bicarbonate salt results in a pH in a range from about 5 to about 9, if in an aqueous solution, and wherein the bicarbonate salt is present in a molar amount equal to the combined molar amount of the glutathione and the organic acid or in a molar excess of the combined molar amount of the glutathione and the organic acid.
5. The method of claim 4 , wherein the molar excess is greater than 1.0 and less than about 1.5.
6. The method of claim 1 , wherein the composition further comprises from about 0.01% to about 5% by weight of a pharmaceutically-acceptable thiocyanate salt.
7. The method of claim 1 , wherein the composition is in the form of a particle.
8. The method of claim 7 , wherein the particle is mixed with a gas or liquid propellant for use in inhalation therapy.
9. The method of claim 1 , comprising the further step of administering to the subject an effective amount of a therapeutic agent.
10. The method of claim 9 , wherein the therapeutic agent is an inhaled corticosteroid (ICS) or bronchodilator.
11. The method of claim 9 , wherein the therapeutic agent is selected from the group consisting of Fluticasone, Budesonide, Mometasone, Ciclesonide, Flunisolide, Beclomethasone, Albuterol, Levalbuterol, Ipratropium, Tiotropium, Formoterol, Arformoterol, Indacaterol, Aclidinium, Pirbuterol and any combination thereof.
12. The method of claim 1 , wherein the glutathione is oxidized glutathione.
13. The method of claim 1 , wherein the glutathione is reduced glutathione.
14. The method of claim 1 , wherein upon administration of the composition to the subject, the concentration of glutathione in the airway surface liquid of the subject is from about 0.1 mM to about 1.0 mM.
15. The method of claim 6 , wherein upon administration of the composition to the subject, the concentration of thiocyanate in the airway surface liquid of the subject is from about 0.5 mM to about 3.0 mM.
16. A method of restoring homeostasis to and/or maintaining homeostasis in a mucosal membrane of a subject with a pulmonary or airway disorder or disease by inhibiting microbial growth in an airway of the subject, comprising administering to the airway of the subject an effective amount of a composition comprising:
a) a glutathione, or a pharmaceutically-acceptable salt of glutathione;
b) an organic acid, or a pharmaceutically-acceptable salt of an organic acid; and
c) a bicarbonate salt,
wherein the pulmonary or airway disorder or disease is selected from the group consisting of chronic inflammatory lung disease, inflammation and/or infection associated with lung transplantation, acute lung rejection, asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD) and any combination thereof, thereby restoring homeostasis to and/or maintaining homeostasis in the mucosal membrane of the subject by inhibiting microbial growth in the airway of the subject.
17. The method of claim 16 , wherein the organic acid is ascorbic acid.
18. The method of claim 16 , wherein the bicarbonate salt is sodium bicarbonate or potassium bicarbonate.
19. The method of claim 16 , wherein the composition further comprises from about 0.01% to about 5% by weight of a pharmaceutically-acceptable thiocyanate salt.
20. A method of inhibiting microbial growth in an airway of a subject, comprising administering to the airway of the subject an effective amount of a composition comprising:
a) a glutathione, or a pharmaceutically-acceptable salt of glutathione;
b) an organic acid, or a pharmaceutically-acceptable salt of an organic acid; and
c) a bicarbonate salt,
thereby inhibiting microbial growth in the airway of the subject.
21. The method of claim 20 , wherein the organic acid is ascorbic acid.
22. The method of claim 20 , wherein the bicarbonate salt is sodium bicarbonate or potassium bicarbonate.
23. The method of claim 20 , wherein the composition further comprises from about 0.01% to about 5% by weight of a pharmaceutically-acceptable thiocyanate salt.
24. The method of claim 1 , wherein the composition is in the form of a solid formulation.
25. The method of claim 16 , wherein the composition is in the form of a solid formulation.
26. The method of claim 20 , wherein the composition is in the form of a solid formulation.